18 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Development of novel CXC chemokine receptor 7 (CXCR7) ligands: selectivity switch from CXCR4 antagonists with a cyclic pentapeptide scaffold.
Kyoto University
Optimized method of G-protein-coupled receptor homology modeling: its application to the discovery of novel CXCR7 ligands.
Pharmadesign
Synthesis, modeling and functional activity of substituted styrene-amides as small-molecule CXCR7 agonists.
Vu University Amsterdam
Discovery and Development of First-in-Class ACKR3/CXCR7 Superagonists for Platelet Degranulation Modulation.
Eberhard Karls University T£Bingen
Discovery and evaluation of non-basic small molecule modulators of the atypical chemokine receptor CXCR7.
Pfizer
Discovery of the Potent, Selective, Orally Available CXCR7 Antagonist ACT-1004-1239.
Idorsia Pharmaceuticals
Discovery of Diphenylacetamides as CXCR7 Inhibitors with Novel ?-Arrestin Antagonist Activity.
Pfizer
Design, Synthesis, and Characterization of Ogerin-Based Positive Allosteric Modulators for G Protein-Coupled Receptor 68 (GPR68).
Icahn School of Medicine At Mount Sinai
Discovery, Synthesis, Pharmacological Profiling, and Biological Characterization of Brintonamides A-E, Novel Dual Protease and GPCR Modulators from a Marine Cyanobacterium.
University of Florida
Discovery of a Novel Small-Molecule Modulator of C-X-C Chemokine Receptor Type 7 as a Treatment for Cardiac Fibrosis.
Pfizer
Structure-Activity Relationship Study of Cyclic Pentapeptide Ligands for Atypical Chemokine Receptor 3 (ACKR3).
Kyoto University
Discovery of Novel 1-Cyclopentenyl-3-phenylureas as Selective, Brain Penetrant, and Orally Bioavailable CXCR2 Antagonists.
Gsk Pharmaceuticals R & D
Discovery of Potent and Orally Bioavailable Macrocyclic Peptide-Peptoid Hybrid CXCR7 Modulators.
Pfizer
